291 related articles for article (PubMed ID: 27273134)
21. Predictors of active cancer thromboembolic outcomes. RIETE experience of the Khorana score in cancer-associated thrombosis.
Tafur AJ; Caprini JA; Cote L; Trujillo-Santos J; Del Toro J; Garcia-Bragado F; Tolosa C; Barillari G; Visona A; Monreal M;
Thromb Haemost; 2017 Jun; 117(6):1192-1198. PubMed ID: 28276571
[TBL] [Abstract][Full Text] [Related]
22. Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data.
Tsubata Y; Kawakado K; Hamai K; Furuya N; Yokoyama T; Saito R; Nakamura A; Masuda T; Hamaguchi M; Kuyama S; Honda R; Senoo T; Nakanishi M; Hotta T; Yamasaki M; Ishikawa N; Fujitaka K; Kubota T; Kobayashi K; Isobe T
Int J Clin Oncol; 2023 Jan; 28(1):69-78. PubMed ID: 36357710
[TBL] [Abstract][Full Text] [Related]
23. The incidence of venous thromboembolism among patients with primary lung cancer.
Chew HK; Davies AM; Wun T; Harvey D; Zhou H; White RH
J Thromb Haemost; 2008 Apr; 6(4):601-8. PubMed ID: 18208538
[TBL] [Abstract][Full Text] [Related]
24. Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy.
Hill H; Robinson M; Lu L; Slaughter D; Amin A; Mileham K; Patel JN
Thromb Res; 2021 Dec; 208():71-78. PubMed ID: 34742139
[TBL] [Abstract][Full Text] [Related]
25. Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre.
Pelletier R
J Oncol Pharm Pract; 2021 Jun; 27(4):911-918. PubMed ID: 33757321
[TBL] [Abstract][Full Text] [Related]
26. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
Lee JH; Hyun DG; Choi CM; Lee JC; Kim WS; Oh YM; Lee SD; Lee JS
Respiration; 2019; 98(3):203-211. PubMed ID: 31096241
[TBL] [Abstract][Full Text] [Related]
27. The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis.
van Es N; Ventresca M; Di Nisio M; Zhou Q; Noble S; Crowther M; Briel M; Garcia D; Lyman GH; Macbeth F; Griffiths G; Iorio A; Mbuagbaw L; Neumann I; Brozek J; Guyatt G; Streiff MB; Baldeh T; Florez ID; Gurunlu Alma O; Agnelli G; Ageno W; Marcucci M; Bozas G; Zulian G; Maraveyas A; Lebeau B; Lecumberri R; Sideras K; Loprinzi C; McBane R; Pelzer U; Riess H; Solh Z; Perry J; Kahale LA; Bossuyt PM; Klerk C; Büller HR; Akl EA; Schünemann HJ;
J Thromb Haemost; 2020 Aug; 18(8):1940-1951. PubMed ID: 32336010
[TBL] [Abstract][Full Text] [Related]
28. Advanced nodal stage predicts venous thromboembolism in patients with locally advanced non-small cell lung cancer.
Li R; Hermann G; Baldini E; Chen A; Jackman D; Kozono D; Nguyen P; Nohria A; Powell G; Mak R
Lung Cancer; 2016 Jun; 96():41-7. PubMed ID: 27133748
[TBL] [Abstract][Full Text] [Related]
29. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
[TBL] [Abstract][Full Text] [Related]
30. Occult cancer-related first venous thromboembolism is associated with an increased risk of recurrent venous thromboembolism.
Gran OV; Braekkan SK; Paulsen B; Skille H; Rosendaal FR; Hansen JB
J Thromb Haemost; 2017 Jul; 15(7):1361-1367. PubMed ID: 28440069
[TBL] [Abstract][Full Text] [Related]
31. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study.
Kruger S; Haas M; Burkl C; Goehring P; Kleespies A; Roeder F; Gallmeier E; Ormanns S; Westphalen CB; Heinemann V; Rank A; Boeck S
Thromb Res; 2017 Sep; 157():9-15. PubMed ID: 28675831
[TBL] [Abstract][Full Text] [Related]
32. [Retrospective Analysis of Risk Factors for Venous Thromboembolism in 283 Patients with Lung Cancer during Systemic Therapy].
Liu Y; Gu Y; Yi F; Cao B
Zhongguo Fei Ai Za Zhi; 2019 Jul; 22(7):419-426. PubMed ID: 31315780
[TBL] [Abstract][Full Text] [Related]
33. [Risk prediction of venous thromboembolism in non-small cell lung cancer patients based on COMPASS-CAT risk assessment model].
Wang YF; Ma F; Liu BL; Yang K; Li JL; Yu L
Zhonghua Zhong Liu Za Zhi; 2020 Apr; 42(4):340-345. PubMed ID: 32375452
[No Abstract] [Full Text] [Related]
34. Predictors of active cancer thromboembolic outcomes: mortality associated with calf deep vein thrombosis.
Salazar Adum JP; Diaz Quintero L; Fuentes HE; Lind BB; Caprini JA; Tafur AJ
Int Angiol; 2017 Dec; 36(6):553-557. PubMed ID: 28541021
[TBL] [Abstract][Full Text] [Related]
35. Development and Validation of a Risk Score for Prediction of Venous Thromboembolism in Patients With Lung Cancer.
Li Z; Zhang G; Zhang M; Mei J; Weng H; Peng Z
Clin Appl Thromb Hemost; 2020; 26():1076029620910793. PubMed ID: 32162530
[TBL] [Abstract][Full Text] [Related]
36. The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy.
Ramos JD; Casey MF; Bamias A; De Giorgi U; Bellmunt J; Harshman LC; Ladoire S; Wong YN; Alva AS; Rosenberg JE; Galsky MD; Yu EY;
Clin Appl Thromb Hemost; 2017 Oct; 23(7):755-760. PubMed ID: 27637910
[TBL] [Abstract][Full Text] [Related]
37. Derivation, validation and assessment of a novel nomogram-based risk assessment model for venous thromboembolism in hospitalized patients with lung cancer: A retrospective case control study.
Li H; Tian Y; Niu H; He L; Cao G; Zhang C; Kaiweisierkezi K; Luo Q
Front Oncol; 2022; 12():988287. PubMed ID: 36300098
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma.
Sanfilippo KM; Carson KR; Wang TF; Luo S; Edwin N; Kuderer N; Keller JM; Gage BF
Res Pract Thromb Haemost; 2022 Jan; 6(1):e12634. PubMed ID: 35028491
[TBL] [Abstract][Full Text] [Related]
39. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
Moik F; Chan WE; Wiedemann S; Hoeller C; Tuchmann F; Aretin MB; Fuereder T; Zöchbauer-Müller S; Preusser M; Pabinger I; Ay C
Blood; 2021 Mar; 137(12):1669-1678. PubMed ID: 33067632
[TBL] [Abstract][Full Text] [Related]
40. Venous thromboembolism in non-small cell lung cancer patients who underwent surgery after induction therapy.
Kaminuma Y; Tanahashi M; Suzuki E; Yoshii N; Niwa H
Gen Thorac Cardiovasc Surg; 2020 Oct; 68(10):1156-1162. PubMed ID: 32274676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
